Article (Published version) (764 Kb) - Free access
Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?
|Published in||Hepatology International. 2018, vol. 12, no. 1, p. 17-25|
|Abstract||One to three per cent of the world's population has hepatitis C virus (HCV) infection, which is not only a major cause of liver disease and cancer but also associated with an increased risk of atherosclerosis, despite an ostensibly favourable lipid profile. Autoantibodies are frequent in HCV infection and emerging evidence shows that autoantibodies could be valuable for cardiovascular disease (CVD) risk stratification. This study investigated a novel independent biomarker of CVD, autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and lipids in patients with chronic HCV before, during and after direct-acting anti-viral (DAA) therapy.|
|Research group||Chimie et protéomique clinique (270)|
|BRIDGE, Simon H et al. Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?. In: Hepatology International, 2018, vol. 12, n° 1, p. 17-25. doi: 10.1007/s12072-018-9842-5 https://archive-ouverte.unige.ch/unige:108516|